Drug Wars
Cambridge University Press (Verlag)
978-1-107-16848-0 (ISBN)
While the shockingly high prices of prescription drugs continue to dominate the news, the strategies used by pharmaceutical companies to prevent generic competition are poorly understood, even by the lawmakers responsible for regulating them. In this groundbreaking work, Robin Feldman and Evan Frondorf illuminate the inner workings of the pharmaceutical market and show how drug companies twist health policy to achieve goals contrary to the public interest. In highly engaging prose, they offer specific examples of how generic competition has been stifled for years, with costs climbing into the billions and everyday consumers paying the price. Drug Wars is a guide to the current landscape, a roadmap for reform, and a warning of what is to come. It should be read by policymakers, academics, patients, and anyone else concerned with the soaring costs of prescription drugs.
Robin Feldman is an award-winning teacher and scholar who has published more than forty articles and books. Feldman has been cited by the White House, members of Congress, and numerous federal agencies, and she has testified before committees of the US House and Senate, as well as the California legislature. In 2016, Feldman was named as one of the Women Leaders in Law and Technology, the only academic to receive the honor. Evan Frondorf's legal work with Robin Feldman has been published in journals at Harvard University, Massachusetts and Stanford University, California, including papers on patent demands and generic pharmaceuticals. He studied economics at Yale University, Connecticut and graduated Phi Beta Kappa and magna cum laude, and he was also named a Rhodes Scholar finalist in 2015. He is the current sportswriter for the Yale Alumni Magazine. At Yale, he was heavily involved in sports broadcasting and served as a deputy sports editor at the Yale Daily News.
Introduction: big scandals, higher prices; 1. The winding road to generic entry; 2. 'Generation 1.0': the rise and fall of traditional pay-for-delay; 3. 'Generation 2.0': complicating pay-for-delay; 4. 'Generation 3.0': new tactics for active obstruction of generics; 5. 'Generation 3.0' continued: obstruction of regulatory pathways; 6. Empirical evidence of a citizen's pathway gone astray; Conclusion: a call for systematic reform.
| Erscheinungsdatum | 17.08.2017 |
|---|---|
| Verlagsort | Cambridge |
| Sprache | englisch |
| Maße | 158 x 235 mm |
| Gewicht | 380 g |
| Themenwelt | Medizin / Pharmazie ► Pharmazie |
| Recht / Steuern ► EU / Internationales Recht | |
| Recht / Steuern ► Privatrecht / Bürgerliches Recht ► Medizinrecht | |
| Technik | |
| ISBN-10 | 1-107-16848-1 / 1107168481 |
| ISBN-13 | 978-1-107-16848-0 / 9781107168480 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
